Nanobiotix completes $100 million follow-on offering of ADSs, Ordinary Shares, and pre-funded warrants

Client(s) Nanobiotix S.A.

Jones Day represented Nanobiotix S.A., a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, in a global follow-on offering of American Depositary Shares, Ordinary Shares, and pre-funded warrants for an aggregate gross proceeds of approximately $100 million.